Skip to main content

Table 2 HER2 and TOP2A gene status and Ki67 protein expression in the BR9601 cohort used for this study

From: Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

  

Amplified

Deleted

Normal

HER2 FISH

274/288 (95.1%)

62 (22.6%)

 

212 (77.4%)

TOP2A FISH

274/288 (95.1%)

25 (9.1%)

48 (17.5%)

201 (73.4%)

  

High

Low

 

Ki67

284/288 (98.6%)

120 (42.3%)

164 (57.7%)

 
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us